HNN3.0
Register
Register
Register

Project cooperationUpdated on 16 January 2026

Mechanistic IgG biology for immune-mediated disease

Professor at Unity Health Toronto

Toronto, Canada

About

Offering expertise in mechanistic IgG biology and immune modulation, with primary application to immune-mediated non-communicable diseases. Focus areas include FcγR- and FcRn-dependent pathways, immune complex formation and clearance, heterogeneity of response to antibody-based interventions, and immune-mediated adverse effects such as cytopenias or bleeding. IVIG is used as a biological reference to interpret immunomodulatory mechanisms and inform optimisation and safety of antibody therapies. Additional expertise includes assessment of antibody-dependent enhancement (ADE) as a cross-cutting safety and risk mechanism relevant to antibody-based interventions across disease areas. Interested in contributing mechanistic and translational insight to collaborative Horizon Europe consortia where immune mechanisms, patient stratification, or therapy optimisation are central.

Similar opportunities

  • Project cooperation

    B-cell mediated immune responses in health and disease.

    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Lesly Calderon

    Principal Investigator at Helmholtz Munich and TUM

    Munich, Germany

  • Project cooperation

    Rapid immune response novel platform, diagnostics prognostics

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Michelle Kilcoyne

    Lecturer in Glycosciences at University of Galway

    Galway, Ireland

  • Project cooperation

    Rapid immune response novel platform, animal free

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing

    Michelle Kilcoyne

    Lecturer in Glycosciences at University of Galway

    Galway, Ireland